Omnicell (OMCL) AI Stock Analysis

• Market Cap: $1.87B
• Dividend Yield: N/A
• Average Volume (3M): 703.01K
• Price to Earnings (P/E): 951.4
• Beta (1Y): 0.28
• Revenue Growth: 10.67%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.40
• Shares Outstanding: 44,876,522
• 10 Day Avg. Volume: 589,353
• 30 Day Avg. Volume: 703,011
• PEG Ratio: -12.16
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 1.76
• P/FCF Ratio: 23.97
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 3.79
• Enterprise Value/Ebitda: 20.83
• 1Y Price Target: $58.20
• Price Target Upside: 41.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 1.88
• Revenue Forecast (FY): $1.24B

• Rating: 54 Neutral
• Price Target: $42.00 ▲(2.19% Upside)
• Action: Reiterated Date: 02/06/26
• Date: Action: Reiterated 02/06/26

The score is held back most by weak technicals (oversold with negative momentum) and very stretched valuation (extremely high P/E with no dividend support). Financially, debt reduction and positive free cash flow help, but thin and volatile profitability remains a key risk. Earnings call guidance is moderately constructive, but tariff-driven margin pressure and recent EPS/cash weakness temper the outlook.

Positive Factors

Balance sheet strength

Rapid deleveraging over two years meaningfully reduces interest and refinancing risk and increases strategic optionality. Lower leverage improves resilience to healthcare budgeting cycles, enables funding for R&D or tuck‑ins without heavy dilution, and gives the company room to execute multi‑year software and service growth plans.

Recurring revenue / ARR expansion

Rising ARR and service revenue expand a predictable, sticky revenue base that smooths cash flow versus lumpy capital equipment sales. A larger installed base increases cross‑sell and renewal opportunities, underpins long‑term revenue visibility, and supports margin improvement as software mix grows.

Product and platform innovation

Transitioning toward cloud‑connected hardware plus Omnisphere platform raises switching costs and enables recurring software monetization. Platform innovation supports long‑term differentiation in hospital workflows, creates higher lifetime value per account, and positions the company to convert hardware installs into sustained ARR.

Negative Factors

Thin, volatile profitability

Very low and inconsistent profitability constrains the company’s ability to reinvest and compound returns on a sizable equity base. Without sustained operating leverage, modest revenue growth may not translate into durable EPS or FCF improvement, keeping funding and return dynamics fragile over the medium term.

Margin headwinds from tariffs and mix

Material tariff and mix pressures have already compressed gross margins and a multi‑year tariff hit is forecast for 2026. If sourcing, pricing, or product mix shifts fail to offset these structural cost pressures, operating margins and free cash flow will remain constrained, limiting durable profitability gains.

Slow near‑term revenue realization for new hardware

New product launches face long hospital capital cycles and financing fits, so revenue from Titan XT may take many quarters to materialize. That structural timing lag keeps hardware revenue volatile and delays the expected shift to higher‑margin software/ARR, increasing execution risk during the transition period.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

How the Company Makes Money

Omnicell generates revenue through multiple streams, primarily by selling its automated dispensing systems and software solutions to healthcare providers. The company earns a significant portion of its revenue from the sale of hardware, including automated medication dispensing units and robotic systems. In addition to hardware sales, Omnicell also offers software solutions, maintenance contracts, and services that enhance the operational capabilities of its clients, creating recurring revenue through subscription and service contracts. Furthermore, strategic partnerships with healthcare organizations and technology providers contribute to its earnings by expanding market reach and integrating its solutions into existing healthcare infrastructures. The combination of these revenue streams allows Omnicell to maintain a robust financial model, driven by ongoing demand for healthcare efficiency and safety improvements.

Omnicell Financial Statement Overview

Summary

Balance sheet strength improved meaningfully with large debt reduction and sizable equity, and cash generation remains solid with positive operating cash flow and free cash flow. However, earnings quality is the main constraint: despite the 2025 revenue rebound, profitability is very thin and has been volatile, and free cash flow declined year-over-year.

Income Statement

Revenue rebounded in 2025 (+60.3% vs. 2024), but profitability deteriorated sharply: net margin fell to ~0.2% (from ~1.1% in 2024) and operating profit was essentially flat/near-zero despite solid gross margin stability (~42–46% range over the period). Results have also been volatile (loss in 2023, strong profitability in 2021), suggesting earnings quality and cost structure are still not consistently controlled.

Balance Sheet

Leverage improved materially, with total debt down to ~$192M in 2025 from ~$383M in 2024 and ~$614M in 2023, while equity remained large (~$1.23B). Total assets are steady (~$2.0B), giving the company flexibility. The key weakness is low recent profitability, which limits returns on the equity base and reduces the balance sheet’s ability to compound value without an earnings recovery.

Cash Flow

Cash generation is a relative bright spot: 2025 operating cash flow was ~$127M and free cash flow was ~$87M, remaining solidly positive. That said, free cash flow declined ~22% in 2025 versus 2024, indicating weaker conversion year-over-year. Over the broader period, cash flow has been materially stronger than the 2022 trough, but the recent downshift and thin net income in 2025 warrant monitoring.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.18B	1.11B	1.15B	1.30B	1.13B
Gross Profit	503.44M	471.00M	499.93M	588.99M	554.65M
EBITDA	96.28M	90.09M	79.98M	96.85M	174.44M
Net Income	2.05M	12.53M	-20.37M	5.65M	77.85M
Balance Sheet
Total Assets	1.97B	2.12B	2.23B	2.21B	2.14B
Cash, Cash Equivalents and Short-Term Investments	196.52M	381.68M	467.97M	341.85M	359.72M
Total Debt	217.18M	382.55M	614.09M	616.74M	541.01M
Total Liabilities	742.91M	877.65M	1.04B	1.08B	995.81M
Stockholders Equity	1.23B	1.24B	1.19B	1.13B	1.15B
Cash Flow
Free Cash Flow	86.89M	151.26M	139.62M	17.04M	202.84M
Operating Cash Flow	127.30M	187.72M	181.09M	77.78M	231.81M
Investing Cash Flow	-60.36M	-52.79M	-55.02M	-58.67M	-412.50M
Financing Cash Flow	-218.32M	-235.58M	23.42M	-20.95M	47.36M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 41.1 is above the 20-day moving average (MA) of 40.55, below the 50-day MA of 45.16, and above the 200-day MA of 35.15, indicating a neutral trend. The MACD of -1.37 indicates Negative momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 87.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CERT	61 Neutral	$1.13B	-687.38	1.03%	―	11.47%	―
GDRX	60 Neutral	$634.74M	22.21	4.54%	―	1.30%	―
TXG	55 Neutral	$2.94B	-65.93	-5.78%	―	1.92%	59.18%
OMCL	54 Neutral	$1.87B	951.39	0.17%	―	10.67%	―
TDOC	53 Neutral	$938.37M	-4.61	-13.93%	―	-2.37%	77.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	46 Neutral	$362.82M	-0.63	-75.47%	―	-16.65%	-71.92%

Omnicell Corporate Events

Omnicell Launches Advanced Titan XT Dispensing System

On December 8, 2025, Omnicell announced the launch of Omnicell Titan XT, an advanced automated dispensing system designed to enhance autonomous medication management. The Titan XT, powered by the cloud-based OmniSphere platform, aims to improve pharmacy control and nursing confidence by offering a connected medication management ecosystem. This innovation is expected to optimize medication inventory management and streamline nursing workflows, marking a significant milestone in Omnicell’s journey towards comprehensive healthcare automation.

The most recent analyst rating on (OMCL) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.